Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Nature - 1 Jun 2025

Hauseman Zachary J, Stauffer Frédéric, Beyer Kim S, Mollé Sandra, Cavicchioli Elena, Marchand Jean-Remy, Fodor Michelle, Viscomi Jessica, Dhembi Anxhela, Katz Stéphanie, Faggion Beatrice, Lanter Mylene, Kerr Grainne, Schildknecht Daniela, Handl Cornelia, Maddalo Danilo, Pissot Soldermann Carole, Brady Jacob, Shrestha Om, Nguyen Zachary, Leder Lukas, Cremosnik Gregor, Lopez Romero Sandra, Hassiepen Ulrich, Stams Travis, Linder Markus, Galli Giorgio G, Guthy Daniel A, King Daniel A, Maira Sauveur-Michel, Thoma Claudio R, Ehmke Veronika, Tordella Luca

Abstract excerpt

Activating mutations in the rat sarcoma (RAS) genes HRAS, NRAS and KRAS collectively represent the most frequent oncogenic driver in human cancer1. They have previously been considered undruggable, but advances in the past few years have led to the clinical development of agents that target KRAS(G12C) and KRAS(G12D) mutants, yielding promises of therapeutic responses at tolerated doses2. However, clinical agents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to High-Throughput Screening Assays

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 40335703
DOI: 10.1038/s41586-025-08931-1
PMCID: PMC12137120

Genes

NRAS
KRAS
HRAS
MRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the SHOC2-RAS interaction in RAS-mutant cancers.PMID 40335703Read ↗

Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.Semantic proximity Read ↗

Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II.Semantic proximity Read ↗

A mutation-resolved therapeutic atlas of NRAS-mutant melanoma reveals genotype-selective response to RAS(ON) inhibition and adaptive STAT3 survivalSemantic proximity Read ↗

Structure of the SHOC2–MRAS–PP1C complex provides insights into RAF activation and Noonan syndromeSemantic proximity Read ↗

Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.Semantic proximity Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Semantic proximity Read ↗

A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions.Semantic proximity Read ↗

Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.Semantic proximity Read ↗

KRAS G12C-mutant driven non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitorsSemantic proximity Read ↗

Structure of the MRAS-SHOC2-PP1C phosphatase complex.Semantic proximity Read ↗

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.